ePrints

Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis( MIRNA): results from the phase 2, randomised, double-blind, double-dummy study

Lookup NU author(s): Professor Quentin AnsteeORCiD

Downloads

• Accepted version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Publication metadata

Author(s): Wong VM, Amin NB, Takahashi H, Darekar A, Tacke F, Kiszko J, Rodriguez H, Nakajima A, Alkhouri N, Charlton M, Anstee QM

Publication type: Article

Publication status: Published

Journal: Lancet Gastroenterology & Hepatology

Year: 2025

Pages: Epub ahead of print

Online publication date: 31/07/2025

Acceptance date: 21/04/2025

Date deposited: 22/04/2025

ISSN (print): 2468-1253

ISSN (electronic): 2468-1156

Publisher: The Lancet Publishing Group

URL: https://doi.org/10.1016/S2468-1253(25)00128-1

DOI: 10.1016/S2468-1253(25)00128-1

ePrints DOI: 10.57711/eg2h-5m06

Data Access Statement: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer might also provide access to the related individual de-identified participant data. See https://www.pfizer.com/science/ clinical-trials/trial-data-and-results for more information.

Altmetrics

Funding

Share